Omnyx, LLC Introduces New Dynamyx™ Software for Exceptional Digital Pathology User Experience
Provides Intuitive Pathology Workflow, Tools to Boost Efficiency and
New Collaboration Capabilities
PITTSBURGH, March 14, 2016 — Omnyx, LLC, a joint venture of GE Healthcare and UPMC, is launching next generation digital pathology software, Dynamyx™, to enhance the way today’s pathologists work and collaborate. Omnyx’s mission is to provide the best tools and resources for pathologists to diagnose cancer faster and more accurately so that every patient outcome is enhanced. Dynamyx software aids clinicians in performing various tasks and delivers more utility for pathologists to help make confident decisions and adapt to a digital workflow through the use of intuitive design and enhanced tools.
Pathologists diagnose cancer and other diseases. This responsibility comes with downstream implications in treatments and care plans. Therefore, getting the diagnosis right matters a great deal to clinicians and patients. The use of digital platforms for aiding in diagnosis permits clinicians to view images and collaborate in real-time, ultimately enhancing care.
“As cancer care increases in volume and complexity, the essential need for technology and innovation mounts. We at Omnyx understand the burden on clinicians and the stakes for patients. Dynamyx represents our direct response to this growing need for healthcare providers,” said Mamar Gelaye, Omnyx CEO. “Dynamyx connects pathologists and other care providers, allowing them to efficiently and securely share their expertise and collaborate. Omnyx is proud to offer more value to the market. We thank the numerous pathologists across the industry and our partners at UPMC for their insights and innovation in informing our efforts on Dynamyx. “
The added capability and advances of this new platform are exciting and are best presented through a demonstration. Please visit us March 14-16 at booth #1122 at the USCAP Annual Meeting in Seattle to view Dynamyx, or contact us at www.Omnyx.com.
Omnyx, LLC, a joint venture of GE Healthcare and UPMC, is helping to transform the way pathologists worldwide work and collaborate. Through our Precision Solution™ that includes smart scanners, brilliant software and transformative consulting, all members of the cancer care team can work together to enhance patient outcomes. Our vision is a world in which efficient and effective cancer diagnosis helps guide personalized patient care. Omnyx® products are for in vitro diagnostic use for specific clinical applications and are intended for research use only on other applications. For more information, visit www.Omnyx.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. www.gehealthcare.com.
A world-renowned health care provider and insurer, Pittsburgh-based UPMC is inventing new models of accountable, cost-effective, patient-centered care. It provides more than $888 million a year in benefits to its communities, including more care to the region’s most vulnerable citizens than any other health care institution. The largest nongovernmental employer in Pennsylvania, UPMC integrates 60,000 employees, more than 20 hospitals, more than 500 doctors’ offices and outpatient sites, a 2.8-million-member health insurance division, and international and commercial operations. Affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC ranks No. 13 in the prestigious U.S. News & World Report annual Honor Roll of America’s Best Hospitals. For more information, go to UPMC.com.
In the European Union, the Omnyx® Precision Solution™ is CE marked under the European Union’s ‘In Vitro Diagnostics Directive’ for in vitro diagnostic use with the VL4 and VL120 scanners, and DPS and Dynamyx™ software.
In Canada, the Omnyx Precision Solution is licensed by Health Canada for in vitro diagnostic use with the VL4 and VL120 scanners, and DPS and Dynamyx software.
In the United States, the Omnyx Precision Solution, consisting of DPS and the VL4 scanner, is cleared by the U.S. Food & Drug Administration for in vitro diagnostic use for Manual Read of the Digital HER2 Application. In the United States, the VL120 scanner and Dynamyx software are for research use only.